These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 36449315)
1. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. Kiluk BD; Kleykamp BA; Comer SD; Griffiths RR; Huhn AS; Johnson MW; Kampman KM; Pravetoni M; Preston KL; Vandrey R; Bergeria CL; Bogenschutz MP; Brown RT; Dunn KE; Dworkin RH; Finan PH; Hendricks PS; Houtsmuller EJ; Kosten TR; Lee DC; Levin FR; McRae-Clark A; Raison CL; Rasmussen K; Turk DC; Weiss RD; Strain EC JAMA Psychiatry; 2023 Jan; 80(1):84-92. PubMed ID: 36449315 [TBL] [Abstract][Full Text] [Related]
2. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks. Camenga DR; Colon-Rivera HA; Muvvala SB J Stud Alcohol Drugs; 2019 Jul; 80(4):393-402. PubMed ID: 31495374 [TBL] [Abstract][Full Text] [Related]
3. Advances in the delivery of buprenorphine for opioid dependence. Rosenthal RN; Goradia VV Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357 [TBL] [Abstract][Full Text] [Related]
4. Developing an opioid use disorder treatment cascade: A review of quality measures. Williams AR; Nunes EV; Bisaga A; Pincus HA; Johnson KA; Campbell AN; Remien RH; Crystal S; Friedmann PD; Levin FR; Olfson M J Subst Abuse Treat; 2018 Aug; 91():57-68. PubMed ID: 29910015 [TBL] [Abstract][Full Text] [Related]
5. Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study. Craft WH; Tegge AN; Keith DR; Shin H; Williams J; Athamneh LN; Stein JS; Chilcoat HD; Le Moigne A; DeVeaugh-Geiss A; Bickel WK Drug Alcohol Depend; 2022 May; 234():109389. PubMed ID: 35287034 [TBL] [Abstract][Full Text] [Related]
6. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)". Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577 [TBL] [Abstract][Full Text] [Related]
7. Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. Chalhoub RM; Kalivas PW Drugs; 2020 Oct; 80(15):1509-1524. PubMed ID: 32776315 [TBL] [Abstract][Full Text] [Related]
8. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115 [TBL] [Abstract][Full Text] [Related]
9. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100 [TBL] [Abstract][Full Text] [Related]
10. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578 [TBL] [Abstract][Full Text] [Related]
11. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events. Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511 [TBL] [Abstract][Full Text] [Related]
12. Medications for Opioid Use Disorder During Incarceration. McDermott-Winger ER; Latham CL J Addict Nurs; 2022 Jul-Sep 01; 33(3):182-190. PubMed ID: 36041161 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic strategies for treating opioid use disorder and overdose. Luba R; Martinez S; Jones J; Pravetoni M; Comer SD Expert Opin Investig Drugs; 2023 Jan; 32(1):77-87. PubMed ID: 36696567 [TBL] [Abstract][Full Text] [Related]
14. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails. Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354 [TBL] [Abstract][Full Text] [Related]
15. Medications for management of opioid use disorder. Koehl JL; Zimmerman DE; Bridgeman PJ Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869 [TBL] [Abstract][Full Text] [Related]
16. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care. Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351 [No Abstract] [Full Text] [Related]
17. Opioid Use Disorder Treatments: An Evidence Map. Sugarman A; Vittitow A; Cheng A; Malone M; McDonald R; Pace N; Williams O; Tofighi B; McNeely J; Schatz D; Roberts T; Hey SP; Garrity K; Lindquist K; Lee JD Drug Alcohol Depend; 2022 Dec; 241():109657. PubMed ID: 36332588 [TBL] [Abstract][Full Text] [Related]
18. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting. Carswell N; Angermaier G; Castaneda C; Delgado F Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678 [TBL] [Abstract][Full Text] [Related]
19. Medication Treatment of Opioid Use Disorder. Bell J; Strang J Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089 [TBL] [Abstract][Full Text] [Related]
20. Opioid use disorder: current trends and potential treatments. Lee YK; Gold MS; Blum K; Thanos PK; Hanna C; Fuehrlein BS Front Public Health; 2023; 11():1274719. PubMed ID: 38332941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]